Jin Yong Lee
Family · Los Angeles, CANPI 1699439356
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 38 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 12.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $730 and has fallen 63.6% since, to $265 in 2025.
Across 38 payments — averaging $30.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$142
- Bristol Myers Squibb$131
- Sanofi-aventis U.S. LLC$125
- Pfizer$86
- Incyte Corporation$83
- Deciphera Pharmaceuticals Inc.$68
- plus $534 from 17 others
What the payments were for
- Food & beverage$1,169100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 5 | $142 |
| Bristol Myers Squibb | 5 | $131 |
| Sanofi-aventis U.S. LLC | 1 | $125 |
| Pfizer | 1 | $86 |
| Incyte Corporation | 3 | $83 |
| Deciphera Pharmaceuticals Inc. | 3 | $68 |
| Exelixis Inc. | 2 | $54 |
| Servier Pharmaceuticals LLC | 2 | $50 |
| AbbVie | 2 | $42 |
| Jazz Pharmaceuticals Inc. | 1 | $40 |
| EMD Serono, Inc. | 1 | $36 |
| Gilead | 1 | $33 |
| Amgen | 1 | $33 |
| Solventum Corporation | 1 | $30 |
| Puma Biotechnology, Inc. | 1 | $30 |
| Blueprint Medicines Corporation | 1 | $28 |
| Organon | 1 | $25 |
| Aadi Bioscience, Inc. | 1 | $25 |
| Eisai Inc. | 1 | $24 |
| Lucid Diagnostics Inc. | 1 | $24 |
| Merck | 1 | $22 |
| Astellas Pharma US Inc | 1 | $20 |
| AstraZeneca | 1 | $17 |
How this compares
$1,169 in reported general payments places this provider in the 75th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 13 | $51,389 |
| Rosuvastatin Calcium | 11 | $248 |
| Atorvastatin Calcium | 15 | $143 |
| Losartan Potassium | 11 | $73 |
| Amlodipine Besylate | 15 | $57 |
| Metformin Hcl | 11 | $48 |
Paid to pharmacies, not to this prescriber.
Other family in Los Angeles
- Annette ShonLos Angeles$406K
- Phyllis CasonLos Angeles$187K
- Theodore SolomonLos Angeles$131K
- Angela SarffLos Angeles$51K
- Karla MenjivarLos Angeles$36K
- Janet GripshoverLos Angeles$30K
- Jualynda SmithLos Angeles$28K
- Phoebedel ReyesLos Angeles$26K
- Ayana ElliottLos Angeles$25K
- Lori RobertsonChino Hills$475K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.